Lbmc Investment Advisors LLC Raises Stock Position in Eli Lilly and Company $LLY

Lbmc Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 92.8% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,470 shares of the company’s stock after purchasing an additional 1,670 shares during the quarter. Lbmc Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $2,648,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in LLY. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the 1st quarter valued at approximately $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $29,000. Steph & Co. raised its stake in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after acquiring an additional 29 shares in the last quarter. Finally, Financial Gravity Companies Inc. purchased a new position in Eli Lilly and Company in the second quarter valued at $31,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Morgan Stanley upped their price target on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a report on Monday, November 24th. Wolfe Research boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Guggenheim restated a “buy” rating and set a $1,163.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Loop Capital set a $950.00 target price on shares of Eli Lilly and Company in a report on Monday, November 10th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Four research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $1,141.73.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,042.06 on Thursday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99. The firm has a market capitalization of $985.14 billion, a PE ratio of 50.98, a price-to-earnings-growth ratio of 1.32 and a beta of 0.37. The stock’s 50-day simple moving average is $951.95 and its 200-day simple moving average is $826.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s payout ratio is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.